A Phase II Trial of Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2016
At a glance
- Drugs Bevacizumab; Paclitaxel; Pemetrexed
- Indications Lung cancer; Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 07 Mar 2016 Results published in the Journal of Thoracic Oncology.
- 31 Jan 2013 Planned End Date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.